Kehua Biology: The delayed announcement of surging funds

--The story of the Cai Xiaoming Capital market revolves around the swine flu virus, and as the early stages of the Rhine Organism (002166) and an gene (002030) in the two-tier market, a large amount of money is also being fought around another diagnostic reagent faucet, the Kehua creature (002022). Kehua Biological on May 27 issued a "clarification bulletin", officially said to have developed a swine influenza virus nucleic acid detection kit.　　The news, however, did not stimulate a sharp rise in share prices in the two-tier market, as the an gene announced in the development of a swine flu test kit. In fact, since May 13, Kehua biological stock prices began to fluctuate violently, from 16.5 yuan to 20 yuan, and then fell back from 20 yuan to 16.5 yuan, since then, in the company "Clarification Bulletin" advertised the day before (May 26), there have been huge fluctuations. The author found that as early as May 13 to May 14, Kehua Biology has developed a flu virus detection kit, but the news was delayed to public disclosure, but in Shanghai local media leaked. In addition, it is clear that some of the "prescient" funds are intervening in the day before Kehua has officially announced the success of the kit.　　The volatility of bio-stock price in the secondary market is related to the lag of the company's information disclosure. The successful time of development and an gene close to Ann Gene was announced on May 11 to develop a successful influenza virus detection kit, and the next day the product specifications. This led to a wave of gains in the price of the gene.　　And the same as domestic testing reagent leading bio-organisms, according to past experience, its research and development strength and emergency response capacity should be said to be no more than the gene is poor, but the company has been delayed to participate in influenza virus detection products research and Development bulletin or statement. But in fact, Kehua biology in the An gene bulletin successfully developed a test kit, its detection reagent has been basically developed successfully. But the news was not officially disclosed, but was leaked to the Shanghai media by the an gene in-house researcher. A Shanghai media published on May 14, "Shanghai to overcome the difficulties of 3 hours to diagnose influenza A" news, the article is mainly in Shanghai research and development institutions have produced a swine flu virus detection products. The article does not specifically point out that the product is developed by the science and technology, but has repeatedly mentioned the main research and development personnel for the Science and Technology Department of Biotechnology director Wang.　　The end of the article also pointed out that the Kehua biology has stated that it will communicate with the relevant State departments, the new reagent into use. And the message published the day before, that is, May 13, Kehua biological two market trend is to start to get rid of the decline, launched on the attack, and on May 14 continued upstream, May 15 strong trading. It is questionable, however, that the Kehua creature remained silent for the next few days, neither announcing the success of reagent development nor responding to previous media reports. In the pursuit of the market, Kehua biological aspects as if not aware of testing reagents, duringThe announcement is only about the previous major scientific research projects to obtain state-specific funds of the content. As a leader in the research and development of domestic testing reagents, the silence of Kehua creatures after the outbreak of swine flu is rather bizarre. But the real situation is that, after the swine flu outbreak, the Kehua began to organize their efforts to develop testing products.　　All this is not known to public investors-but the information is on the brokerage's research report. In a brokerage May 14 research Report, detailed description of the process of the development of bio-Chinese biology: As early as May 6, Kehua Biology was invited by the Registrar of SFDA medical devices to attend a seminar in Beijing on in vitro diagnostic reagents and medical protective products for swine flu.　　Since then rely on a strong research and development strength, to May 14 before and after the relevant product trial success. Before the official announcement, the stock price fluctuated violently because the Kehua creature had not been officially announced, the news of the development of a H1N1 test product by the biotech community had not been confirmed by public investors. In the secondary market, the Kehua creature on May 16 to create a new high of 20 yuan, to May 25 all the way back to 16.5 yuan to start the price.　　However, this seems to be another wave of the beginning of a huge shock market-May 26, the formal announcement of the bio-China biological testing products, the day before, some "foresight" of funds in the plate staged a lot of empty battle. May 26 afternoon, Kehua from the original decline of about 1% of the situation, in half an hour was pulled up to close to the limit of position, the plate in the bill enthusiastically, and sometimes more than 10,000 hands to pay the bill. But then again under the pressure of a huge sales list from close to trading back to the day of 2% of the position. At the same time, the biological amplitude of the 11.26%, the most amplitude since this year.　　May 27, Kehua Biological and "just" officially announced the development of a test products. Looking at the information disclosure of Kehua since the outbreak of influenza A (H1N1), it can be seen that there has been a surge of funds behind the company's lagging information disclosure, while public investors have been unable to learn the latest product development from the official channels. In sharp contrast to this is the gene, in the successful trial test products, the announcement, and the impact of the product on the company detailed description. Kehua organisms may need to reflect on the disclosure of information related to emergency events.